Dana Hambly - National Health Director of Investor Relations
| NHI Stock | USD 77.87 0.73 0.95% |
Director
Mr. Dana Hambly is Director of Investor Relations of the Company. Previously, Hambly served as Senior Vice President and Equity Research Analyst at Stephens Inc., where he covered publicly traded REITs, including NHI, and healthcare companies in behavioral health, postacute health, senior housing, physician staffing, outpatient surgery, and various other postacute services industries. Hambly graduated from Georgetown University with a B.A. and received his MBA from Vanderbilt University Owen Graduate School of Management in 2006. since 2019.
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 222 Robert Rose Drive, Murfreesboro, TN, United States, 37129-6346 |
| Phone | 615 890 9100 |
| Web | https://www.nhireit.com |
National Health Management Efficiency
The company has Return on Asset of 0.047 % which means that on every $100 spent on assets, it made $0.047 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0993 %, implying that it generated $0.0993 on every 100 dollars invested. National Health's management efficiency ratios could be used to measure how well National Health manages its routine affairs as well as how well it operates its assets and liabilities. As of now, National Health's Return On Tangible Assets are decreasing as compared to previous years. The National Health's current Return On Capital Employed is estimated to increase to 0.09, while Return On Equity is projected to decrease to 0.10. As of now, National Health's Return On Assets are decreasing as compared to previous years. The National Health's current Asset Turnover is estimated to increase to 0.17, while Total Assets are projected to decrease to under 1.3 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Kapila Anand | Omega Healthcare Investors | 67 | |
| Christann Vasquez | Healthcare Realty Trust | 60 | |
| John Abbott | Healthcare Realty Trust | 66 | |
| Walter Rakowich | Ventas Inc | 63 | |
| Kevin Jacobs | Omega Healthcare Investors | 47 | |
| Edward Braman | Healthcare Realty Trust | 64 | |
| Richard Gilchrist | Ventas Inc | 74 | |
| Nancy Agee | Healthcare Realty Trust | 68 | |
| Alan Gardner | Community Healthcare Trust | 67 | |
| Burke Whitman | Omega Healthcare Investors | 64 | |
| Melody Barnes | Ventas Inc | 56 | |
| Barbara Hill | Omega Healthcare Investors | 67 | |
| Henry Cole | Global Medical REIT | 76 | |
| Paula Crowley | Global Medical REIT | 66 | |
| Sean Nolan | Ventas Inc | 52 | |
| Peter Lyle | Healthcare Realty Trust | 56 | |
| Bruce Sullivan | Healthcare Realty Trust | 79 | |
| Claire Gulmi | Community Healthcare Trust | 67 | |
| Robert Reed | Ventas Inc | 68 | |
| Huiqi Zhang | Global Medical REIT | 31 | |
| Edward Lowenthal | Omega Healthcare Investors | 75 | |
Management Performance
| Return On Equity | 0.0993 | ||||
| Return On Asset | 0.047 |
National Health Investors Leadership Team
Elected by the shareholders, the National Health's board of directors comprises two types of representatives: National Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of National. The board's role is to monitor National Health's management team and ensure that shareholders' interests are well served. National Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, National Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Travis, Senior Vice President Chief Accounting Officer | ||
| Robert Adams, Independent Director | ||
| James Jobe, Independent Director | ||
| John Spaid, Chief Financial Officer, Executive Vice President - Finance | ||
| Eric Mendelsohn, CEO President | ||
| W Adams, Independent Chairman of the Board | ||
| Michelle Kelly, Senior Investments | ||
| Robert Webb, Independent Director | ||
| Susan Sidwell, Corporate Secretary | ||
| Dana Hambly, Director of Investor Relations | ||
| Robert McCabe, Independent Director | ||
| Kimberly Ouimet, Director Resources | ||
| Colleen Schaller, Director of Investor Relations | ||
| Charlotte Swafford, Independent Director | ||
| Kristin Gaines, Chief Credit Officer | ||
| Kevin Pascoe, Executive VP of Investments | ||
| D Mendelsohn, Executive Vice President - Corporate Finance |
National Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is National Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0993 | ||||
| Return On Asset | 0.047 | ||||
| Profit Margin | 0.38 % | ||||
| Operating Margin | 0.63 % | ||||
| Current Valuation | 4.66 B | ||||
| Shares Outstanding | 45.42 M | ||||
| Shares Owned By Insiders | 4.67 % | ||||
| Shares Owned By Institutions | 67.94 % | ||||
| Number Of Shares Shorted | 1.35 M | ||||
| Price To Earning | 13.23 X |
Currently Active Assets on Macroaxis
When determining whether National Health Investors offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of National Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of National Health Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on National Health Investors Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in National Health Investors. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Diversified REITs space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of National Health. If investors know National will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about National Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.14) | Dividend Share 3.6 | Earnings Share 2.91 | Revenue Per Share 7.598 | Quarterly Revenue Growth (0.12) |
The market value of National Health Investors is measured differently than its book value, which is the value of National that is recorded on the company's balance sheet. Investors also form their own opinion of National Health's value that differs from its market value or its book value, called intrinsic value, which is National Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because National Health's market value can be influenced by many factors that don't directly affect National Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between National Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if National Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, National Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.